Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

EPZICOM

ABACAVIR;LAMIVUDINE

Standard Dose
600MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary

Approval overview EPZICOM is listed in Drugs@FDA under application 204004 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;LAMIVUDINE Form and strength TABLET;ORAL - 600MG;300MG Sponsor MYLAN PHARMS INC Submission history Latest submission status date: 2016-01-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview EPZICOM is listed in Drugs@FDA under application 204004 (ANDA). Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;LAMIVUDINE Form and strength TABLET;ORAL - 600MG;300MG Sponsor MYLAN PHARMS INC Submission history Latest submission status date: 2016-01-15 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)

Interaction Notes

  • No interaction notes stored yet.